Exelixis
Trade Exelixis 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
Stock Snapshot
The current Exelixis(EXEL) stock price is $41.25, with a market capitalization of 10.94B. The stock trades at a price-to-earnings (P/E) ratio of 17.18.
During the trading session on 2025-11-08, Exelixis(EXEL) shares reached a daily high of $41.25 and a low of $39.93. At a current price of $41.25, the stock is +3.3% higher than the low and still 0.0% under the high.
Trading volume for Exelixis(EXEL) stock has reached 2.32M, versus its average volume of 2.87M.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.
EXEL News
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $45 from $44 and keeps an Overweight rating on the shares. Cabo continues to demonstrate sus...
Earlier this week, Exelixis reported third-quarter 2025 earnings with revenue of US$597.76 million and net income of US$193.58 million, both up from the prior y...
Analyst ratings
57%
of 21 ratingsMore EXEL News
Shares of Amgen Inc. ( AMGN ) climbed 7.8% after the company reported third-quarter adjusted earnings of $5.64 per share, surpassing the Zacks Consensus Estimat...
Exelixis ((EXEL)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premiu...
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $49 from $46 and keeps a Buy rating on the shares following the Q3 rep...
Analyst Yaron Werber of TD Cowen maintained a Buy rating on Exelixis, with a price target of $51.00. Elevate Your Investing Strategy: Take advantage of TipRanks...
Exelixis ( (EXEL) ) has released its Q3 earnings. Here is a breakdown of the information Exelixis presented to its investors. Elevate Your Investing Strategy:...
Earnings Call Insights Exelixis narrows 2025 revenue guidance to $2.3B–$2.35B amid accelerated GI franchise expansion and new pivotal trials Nov. 04, 2025 9:06...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...